Book Online or Call 1-855-SAUSALITO

Sign In  |  Register  |  About Sausalito  |  Contact Us

Sausalito, CA
September 01, 2020 1:41pm
7-Day Forecast | Traffic

  • Search Hotels in Sausalito

  • CHECK-IN:
  • CHECK-OUT:
  • ROOMS:
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Novartis AG Common Stock (NY: NVS )

99.07 -0.30 (-0.30%)
Official Closing Price Updated: 7:00 PM EST, Jan 15, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Novartis AG Common Stock

< Previous 1 2
...
19 20 21 22 23 24 25 26 27
...
42 43 Next >
10 Health Care Stocks Whale Activity In Today's Session
This whale alert can help traders discover the next big trading opportunities. Whales are entities with large sums of money and we track their transactions here at Benzinga on our options activity... 
Via Benzinga
Thoughts For Thursday: Correction Day!
The market remains agitated and it looks like it may be a long week from here to Thanksgiving. Yesterday the market remained chiefly in corrective mode, as it was down from the outset. 
Via Talk Markets
Novartis Mulls Disposing Its Non-Core Ophthalmology and Respiratory Units
Novartis AG (NYSE: NVS) is reportedly weighing divesting non-core assets as it seeks to raise money to invest in cutting-edge medicines, people familiar with the matter said. 
Via Benzinga
BioNTech Plans To Set Up Singapore Based mRNA Plant By End Of 2023
Via Benzinga
Should Income Investors Buy This High-Yielding Dividend Stock?
Novartis' product portfolio and pipeline bode well for its future. 
Via The Motley Fool
Novartis (NVS) Q3 2022 Earnings Call Transcript
NVS earnings call for the period ending September 30, 2022. 
Via The Motley Fool
Novartis Offers Mixed Earnings Report As It Approaches A Key Spinoff
The spinoff will help Novartis become a "pure-play" innovative medicines giant, the company says. 
Via Investor's Business Daily
Novartis Clocks 4% Drop In Quarterly Sales, Once Again Perks Up Sandoz Earnings Outlook
Via Benzinga
Biogen, Seagen Name New CEOs — But One Biotech Stock Crumbles
Biogen jumped after naming Christopher Viehbacher its CEO. David Epstein will take over at Seagen. 
Via Investor's Business Daily
Drug Repurposing Market to Eyewitness Huge Growth by 2027 : Allergan, Astellas Pharma, Biovista, NuMedii
Stay up-to-date with Drug Repurposing Market research offered by AMA. Check how key trends and emerging drivers are shaping this industry growth. 
Via SBWire
Exposures Product Safety
Leading Data Analytics Company Vizlib Gains ISO 27001 Certification
About Vizlib Vizlib has revolutionised the way businesses of every size can get more from their data analytics investment into Qlik. With over 1,000 enterprise and public sector clients across the... 
Via PRUnderground
2 Biotech Stocks That Could Make You Richer
Both drugmakers are pretty close to their 52-week highs, but that shouldn't stop investors. 
Via The Motley Fool
Earnings Scheduled For October 25, 2022
Companies Reporting Before The Bell • UBS Gr (NYSE:UBS) is expected to report earnings for its third quarter. • SAP (NYSE:SAP) is expected to report earnings for its third quarter. 
Via Benzinga
After FDA, European Agency Limits Use Of Certain JAK Inhibitors Amid Safety Concerns
Via Benzinga
3 High-Yielding Dividend Stocks That You Can Buy and Hold Forever
These stocks are all trading close to their 52-week lows. 
Via The Motley Fool
Cytokinetics CEO: Why It's OK Not Being An Overnight Success
The company hopes to come out next year with at least one heart-failure drug. 
Via Investor's Business Daily
Twitter Considers Crypto Wallet, Geopolitical Woes To Keep Tesla Shares Volatile, Juul Explores Possible Bailout: Top Stories Tuesday, Oct. 25
Benzinga 
Via Benzinga
Biosimilars Are Revolutionizing Healthcare: Is This Industry Leader a Buy?
Biosimilars are bringing down prescription drug costs without sacrificing quality. 
Via The Motley Fool
US Stock Futures Down; Big Tech Earnings In Focus
Pre-open movers U.S. stock futures traded lower in early pre-market trade on Tuesday after recording gains in the previous session. The Dow Jones jumped by more than 400 points on Monday after all the... 
Via Benzinga
Recap: Novartis Q3 Earnings
Novartis (NYSE:NVS) reported its Q3 earnings results on Tuesday, October 25, 2022 at 01:00 AM. Here's what investors need to know about the announcement. Earnings Novartis beat estimated earnings by... 
Via Benzinga
A Look Into Healthcare Sector Value Stocks
What are Value Stocks? A value stock is traditionally defined in terms of how investors in the marketplace are valuing that company's future growth prospects. Low P/E multiples are good base indicators... 
Via Benzinga
Novartis Experimental Drug Shows Meaningful Superiority Over Previous Treatment In Rare Blood Disorder
Novartis AG's (NYSE: NVS) investigational oral monotherapy iptacopan was superior to anti-C5 therapies (eculizumab or ravulizumab) in adults with paroxysmal nocturnal hemoglobinuria (PNH).  
Via Benzinga
Alcon: Take A Look At Vision Care
Alcon AG is a global provider of ophthalmic surgery and vision care products. We have a favorable view of the company’s market position and product pipeline, and note that sales growth has outpaced... 
Via Talk Markets
Precision Medicine Could Get Even More Precise With Allarity Therapeutics' "Next-Generation" Diagnostics Platform
Allarity Therapeutics Inc. (NASDAQ: ALLR) is a clinical-stage pharmaceutical company focused on oncology treatments. 
Via Benzinga
Pharma Trend Honors the Best Pharmaceutical Companies and the Most Innovative Products 2022
Via Magic PR
Exposures COVID-19
Global Topical Pain Relief Gel Industry Size,Chain Research Report 2022-2028:Johnson & Johnson, Novartis, GlaxoSmithKline
Global Topical Pain Relief Gel Industry Research Report, Growth Trends and Competitive Analysis 2022-2028 
Via SBWire
Topics Economy
Exposures Supply Chain
Biden Asked OPEC+ To Delay Output Decision, Elon Musk Faces Federal Probe Over Twitter Deal, Netflix Ad-Supported Plan: Top Stories Friday, Oct. 14
Reuters Twitter Says Elon Musk Under Federal Probe Over $44B Twitter Deal, In Court Filing 
Via Benzinga
Novartis Fails To Prevent Generic Competition For Its Blockbuster Multiple Sclerosis Drug
The U.S. Supreme Court rejected Novartis AG's (NYSE: NVS) effort to block the launch of generic versions of its multiple sclerosis drug Gilenya. 
Via Benzinga
Bone Cancer Market Overview, Industry Top Manufactures, Size, Growth Rate 2022- 2028:Amgen, Baxter, Bayer
Bone Cancer Market - The new report on the global Bone Cancer Market comes out as an extremely useful resource that helpsplayers to gain a competitive edge over their toughest competitors. It can be... 
Via SBWire
Roche's Muscular Atrophy Treatment Improves Motor Function In Pretreated Patients
Via Benzinga
< Previous 1 2
...
19 20 21 22 23 24 25 26 27
...
42 43 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
 
 
About Us | Contact Us | Privacy Policy | User Agreement | Advertise With Us | Site Map
Photos copyright by Jay Graham Photographer
Copyright © 2010-2020 Sausalito.com & California Media Partners, LLC. All rights reserved.